ArticleEuropean heart journal open2026
Genotype status and arrhythmic risk in sport participants with hypertrophic cardiomyopathy.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The impact of genotype on arrhythmic risk in sports-active hypertrophic cardiomyopathy (HCM) patients remains unclear. We compared outcomes between genotype-positive (G+) and genotype-negative (G-) athletes with HCM. Methods and results: In this retrospective study, HCM patients actively engaged in sports underwent standardized baseline evaluation and follow-up. The primary endpoint included sudden cardiac death (SCD)/sudden cardiac arrest, appropriate implantable cardioverter-defibrillator (ICD) therapy, sustained ventricular tachycardia/non-sustained ventricular tachycardia (NSVT). Secondary outcomes included a composite of ventricular arrhythmias, atrial fibrillation, ischaemic stroke, and heart-failure hospitalization. Fifty-nine patients [age 40 years (23.2-50.0)] were followed for 6.3 years (3.0-12.6). Twenty-nine participants (49.2%) carried a likely pathogenic or pathogenic variant, most commonly MYBPC3 (44.8%), MYH7 (24.1%), and TNNT2 (17.2%). At inclusion, median sport practice was 6.0 (3.0-10.0) hours per week, with 67.8% of competitors. At last follow-up, 88.1% remained active in sports. The ESC 5-year SCD risk score was slightly higher in G+ compared with G- patients [1.87% (1.47-3.67) vs. 1.54% (1.24-2.20), Conclusion: In this exploratory cohort of sports-active HCM patients, ventricular arrhythmic and cardiovascular event rates were similar between G+ and G- participants during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.